Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ocumension Therapeutics ( (HK:1477) ) just unveiled an announcement.
Ocumension Therapeutics has updated investors on its share repurchase activity, disclosing that the number of shares bought back and held in treasury has increased from 17,086,000 as of 31 December 2024 to 20,949,500 as of 19 December 2025. The company stated that these treasury shares may be used in line with applicable regulations, including potential sale for cash, transfer, or cancellation, signaling continued capital management activity without altering any other information disclosed in its latest annual report.
The most recent analyst rating on (HK:1477) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.
More about Ocumension Therapeutics
Ocumension Therapeutics, incorporated in the Cayman Islands and listed in Hong Kong, operates in the biopharmaceutical sector with a focus on ophthalmology, developing and commercializing treatments for eye-related diseases in Greater China and other markets.
Average Trading Volume: 1,290,374
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.69B
See more insights into 1477 stock on TipRanks’ Stock Analysis page.